Anticancer Drug Development, System Updating and Global Participations

Author(s): Da-Yong Lu*, Ting-Ren Lu, En-Hong Chen, Nagendra Sastry Yarla, Bin Xu, Jian Ding, Hong Zhu

Journal Name: Current Drug Therapy

Volume 12 , Issue 1 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Background: New anticancer drug discovery, development and manufacture entered the bottleneck stage. Many limitations of both technology and animal models slow down the anticancer drug developments

Objective: To ease economic burdens for drug developers and general patient populations.

Methods: Key factors affecting anticancer drug developments and possible roadmaps for updating drug screening routines worldwide are suggested.

Results: Drug development chains must be updated and better drug development paradigms must be established.

Conclusions: This world welcomes global participations in anticancer drug developments and utilities.

Keywords: Anticancer drug development, neoplasm metastasis, cost-effective, medicinal chemistry, animal models, drug toxicity, cancer stem cells, individualized cancer therapy.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [37 - 45]
Pages: 9
DOI: 10.2174/1574885511666161025122906
Price: $65

Article Metrics

PDF: 18